{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:15:33Z","timestamp":1790435733732,"version":"4.1.0"},"reference-count":47,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human T cells genetically modified to express chimeric antigen receptors (CAR) specific to the B cell tumor antigen CD19 can successfully eradicate systemic human CD19+ tumors in immunocompromised SCID (severe combined immunodeficient)-Beige mice. However, in the clinical setting, CD4+ CD25hi T regulatory cells (Treg) present within the tumor microenvironment may be potent suppressors of tumor-targeted effector T cells. In order to assess the impact of Tregs on CAR-modified T cells in the SCID-Beige xenotransplant model, we isolated, genetically targeted and expanded natural T regulatory cells (nTreg). In vitro nTregs modified to express CD19-targeted CARs efficiently inhibited the proliferation of activated human T cells, as well as the capacity of CD19-targeted 19-28z+ effector T cells to lyse CD19+ Raji tumor cells. Intravenous infusion of CD19-targeted nTregs into SCID-Beige mice with systemic Raji tumors traffic to sites of tumor and recapitulate a clinically relevant hostile tumor microenvironment. Antitumor efficacy of subsequently infused 19-28z+ effector T cells was fully abrogated as assessed by long-term survival of treated mice. Optimal suppression by genetically targeted nTregs was dependent on nTreg to effector T-cell ratios and in vivo nTreg activation. Prior infusion of cyclophosphamide in the setting of this nTreg-mediated hostile microenvironment was able to restore the antitumor activity of subsequently infused 19-28z+ effector T cells through the eradication of tumor-targeted nTregs. These findings have significant implications for the design of future clinical trials utilizing CAR-based adoptive T-cell therapies of cancer. Cancer Res; 71(8); 2871\u201381. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/0008-5472.can-10-0552","type":"journal-article","created":{"date-parts":[[2011,4,13]],"date-time":"2011-04-13T02:42:55Z","timestamp":1302662575000},"page":"2871-2881","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["<i>In vivo<\/i>Inhibition of Human CD19-Targeted Effector T Cells by Natural T Regulatory Cells in a Xenotransplant Murine Model of B Cell Malignancy"],"prefix":"10.1158","volume":"71","author":[{"given":"James C.","family":"Lee","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Hayman","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hollie J.","family":"Pegram","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elmer","family":"Santos","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Heller","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"},{"name":"Authors' Affiliations:\u20081Center for Cell Engineering, 2Department of Medicine, 3Department of Radiology, 4Department of Epidemiology and Statistics, and 5Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center, New York, New York; and 6Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2011,4,13]]},"reference":[{"key":"2022061702395626400_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2022061702395626400_bib2","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"2022061702395626400_bib3","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2022061702395626400_bib4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1365-2141.2008.07145.x","article-title":"The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma","volume":"142","author":"Cheadle","year":"2008","journal-title":"Br J Haematol"},{"key":"2022061702395626400_bib5","doi-asserted-by":"crossref","first-page":"5454","DOI":"10.1182\/blood-2009-08-232967","article-title":"Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice","volume":"114","author":"James","year":"2009","journal-title":"Blood"},{"key":"2022061702395626400_bib6","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"2022061702395626400_bib7","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2022061702395626400_bib8","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"2022061702395626400_bib9","doi-asserted-by":"crossref","first-page":"4233","DOI":"10.1182\/blood-2007-07-099226","article-title":"Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity","volume":"111","author":"Movahedi","year":"2008","journal-title":"Blood"},{"key":"2022061702395626400_bib10","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1600-065X.2006.00442.x","article-title":"Immune resistance orchestrated by the tumor microenvironment","volume":"213","author":"Gajewski","year":"2006","journal-title":"Immunol Rev"},{"key":"2022061702395626400_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1053\/j.gastro.2008.03.020","article-title":"A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells","volume":"135","author":"Hoechst","year":"2008","journal-title":"Gastroenterology"},{"key":"2022061702395626400_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1084\/jem.20060772","article-title":"CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells","volume":"203","author":"Liu","year":"2006","journal-title":"J Exp Med"},{"key":"2022061702395626400_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ni1178","article-title":"Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self","volume":"6","author":"Sakaguchi","year":"2005","journal-title":"Nat Immunol"},{"key":"2022061702395626400_bib14","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.4049\/jimmunol.160.3.1212","article-title":"CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells","volume":"160","author":"Suri-Payer","year":"1998","journal-title":"J Immunol"},{"key":"2022061702395626400_bib15","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.coi.2003.09.011","article-title":"Control of immune homeostasis by naturally arising regulatory CD4+ T cells","volume":"15","author":"Gavin","year":"2003","journal-title":"Curr Opin Immunol"},{"key":"2022061702395626400_bib16","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med"},{"key":"2022061702395626400_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S1074-7613(02)00280-7","article-title":"CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor","volume":"16","author":"McHugh","year":"2002","journal-title":"Immunity"},{"key":"2022061702395626400_bib18","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1084\/jem.192.2.295","article-title":"Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation","volume":"192","author":"Read","year":"2000","journal-title":"J Exp Med"},{"key":"2022061702395626400_bib19","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","article-title":"Regulatory T cells in cancer","volume":"108","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"2022061702395626400_bib20","first-page":"606","article-title":"Increase of regulatory T cells in the peripheral blood of cancer patients","volume":"9","author":"Wolf","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2022061702395626400_bib21","doi-asserted-by":"crossref","first-page":"10145","DOI":"10.1158\/0008-5472.CAN-06-1822","article-title":"Attenuation of CD8(+) T-cell function by CD4(+)CD25(+) regulatory T cells in B-cell non-Hodgkin's lymphoma","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res"},{"key":"2022061702395626400_bib22","doi-asserted-by":"crossref","first-page":"e1983","DOI":"10.1371\/journal.pone.0001983","article-title":"Treg depletion inhibits efficacy of cancer immunotherapy: implications for clinical trials","volume":"3","author":"Curtin","year":"2008","journal-title":"PLoS ONE"},{"key":"2022061702395626400_bib23","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.molmed.2007.01.003","article-title":"Natural regulatory T cells: mechanisms of suppression","volume":"13","author":"Miyara","year":"2007","journal-title":"Trends Mol Med"},{"key":"2022061702395626400_bib24","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1172\/JCI32446","article-title":"Adoptive T cell therapy for cancer in the clinic","volume":"117","author":"June","year":"2007","journal-title":"J Clin Invest"},{"key":"2022061702395626400_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1479-5876-6-12","article-title":"Transient T cell depletion causes regression of melanoma metastases","volume":"6","author":"Rasku","year":"2008","journal-title":"J Transl Med"},{"key":"2022061702395626400_bib26","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1200\/JCO.2005.00.240","article-title":"Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma","volume":"23","author":"Dudley","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022061702395626400_bib27","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ncponc0666","article-title":"Increased intensity lymphodepletion and adoptive immunotherapy\u2013how far can we go?","volume":"3","author":"Muranski","year":"2006","journal-title":"Nat Clin Pract Oncol"},{"key":"2022061702395626400_bib28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jim.2006.06.014","article-title":"Efficient and reproducible large-scale isolation of human CD4+ CD25+ regulatory T cells with potent suppressor activity","volume":"315","author":"Wichlan","year":"2006","journal-title":"J Immunol Methods"},{"key":"2022061702395626400_bib29","doi-asserted-by":"crossref","first-page":"8338","DOI":"10.4049\/jimmunol.177.12.8338","article-title":"Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients","volume":"177","author":"Battaglia","year":"2006","journal-title":"J Immunol"},{"key":"2022061702395626400_bib30","doi-asserted-by":"crossref","first-page":"320","DOI":"10.4049\/jimmunol.178.1.320","article-title":"Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin","volume":"178","author":"Strauss","year":"2007","journal-title":"J Immunol"},{"key":"2022061702395626400_bib31","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","article-title":"Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen","volume":"1","author":"Gong","year":"1999","journal-title":"Neoplasia"},{"key":"2022061702395626400_bib32","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1182\/blood-2004-10-3932","article-title":"Rapamycin selectively expands CD4+CD25+FoxP3 +regulatory T cells","volume":"105","author":"Battaglia","year":"2005","journal-title":"Blood"},{"key":"2022061702395626400_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1365-3083.2006.01825.x","article-title":"An optimized method for the functional analysis of human regulatory T cells","volume":"64","author":"Oberg","year":"2006","journal-title":"Scand J Immunol"},{"key":"2022061702395626400_bib34","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nm.1930","article-title":"Sensitive in vivo imaging of T cells using a membrane-bound Gaussia princeps luciferase","volume":"15","author":"Santos","year":"2009","journal-title":"Nat Med"},{"key":"2022061702395626400_bib35","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/intimm\/10.12.1969","article-title":"Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic\/suppressive state","volume":"10","author":"Takahashi","year":"1998","journal-title":"Int Immunol"},{"key":"2022061702395626400_bib36","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1084\/jem.188.2.287","article-title":"CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production","volume":"188","author":"Thornton","year":"1998","journal-title":"J Exp Med"},{"key":"2022061702395626400_bib37","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jim.2008.01.012","article-title":"Comparative methodologies of regulatory T cell depletion in a murine melanoma model","volume":"333","author":"Matsushita","year":"2008","journal-title":"J Immunol Methods"},{"key":"2022061702395626400_bib38","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1084\/jem.155.4.1063","article-title":"Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells","volume":"155","author":"North","year":"1982","journal-title":"J Exp Med"},{"key":"2022061702395626400_bib39","first-page":"1671","article-title":"Effect of low dose cyclophosphamide on the immune system of cancer patients: depletion of CD4+, 2H4+ suppressor-inducer T-cells","volume":"48","author":"Berd","year":"1988","journal-title":"Cancer Res"},{"key":"2022061702395626400_bib40","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1182\/blood-2005-02-0642","article-title":"Reduced frequencies and suppressive function of CD4+ CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine","volume":"106","author":"Beyer","year":"2005","journal-title":"Blood"},{"key":"2022061702395626400_bib41","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1158\/0008-5472.CAN-07-6621","article-title":"Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells","volume":"68","author":"Serafini","year":"2008","journal-title":"Cancer Res"},{"key":"2022061702395626400_bib42","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1038\/sj.leu.2404366","article-title":"Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells","volume":"20","author":"Loskog","year":"2006","journal-title":"Leukemia"},{"key":"2022061702395626400_bib43","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1002\/eji.200939432","article-title":"Alloantigen-specific de novo-induced Foxp3+ Treg revert in vivo and do not protect from experimental GVHD","volume":"39","author":"Koenecke","year":"2009","journal-title":"Eur J Immunol"},{"key":"2022061702395626400_bib44","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/eji.200324455","article-title":"Activation requirements for the induction of CD4+CD25+ T cell suppressor function","volume":"34","author":"Thornton","year":"2004","journal-title":"Eur J Immunol"},{"key":"2022061702395626400_bib45","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1517\/14728222.12.6.769","article-title":"Regulatory T cells as therapeutic target in Hodgkin's lymphoma","volume":"12","author":"Koenecke","year":"2008","journal-title":"Expert Opin Ther Targets"},{"key":"2022061702395626400_bib46","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/eji.200324181","article-title":"CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative","volume":"34","author":"Ghiringhelli","year":"2004","journal-title":"Eur J Immunol"},{"key":"2022061702395626400_bib47","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1172\/JCI35890","article-title":"CD4+CD25 +Tregs control the TRAIL-dependent cytotoxicity of tumor-infiltrating DCs in rodent models of colon cancer","volume":"118","author":"Roux","year":"2008","journal-title":"J Clin Invest"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/8\/2871\/2664075\/2871.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/71\/8\/2871\/2664075\/2871.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T08:16:18Z","timestamp":1686039378000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/71\/8\/2871\/572143\/In-vivo-Inhibition-of-Human-CD19-Targeted-Effector"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,13]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,4,13]]},"published-print":{"date-parts":[[2011,4,15]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-10-0552","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,13]]}}}